The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies

Barratt J, Kim SG, Agha I et al. (2023) WNC 23-1175 updated interim results of a phase 1/2 study of bion-1301 in patients with IgA nephropathy. Kidney Int Rep 8:S280–S281. https://doi.org/10.1016/j.ekir.2023.02.632 BarrattJ KimSG AghaI 2023 WNC 23-1175 updated interim results of a phase 1/2 study of bion-1301 in patients with IgA nephropathy Kidney Int Rep 8 S280 S281 https://doi.org/10.1016/j.ekir.2023.02.632 Search in Google Scholar

Benson MJ, Dillon SR, Castigli E et al. (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655–3659. https://doi.org/10.4049/jimmunol.180.6.3655 BensonMJ DillonSR CastigliE 2008 Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL J Immunol 180 3655 3659 https://doi.org/10.4049/jimmunol.180.6.3655 Search in Google Scholar

Bosello S, Youinou P, Daridon C et al. (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256–1264. BoselloS YouinouP DaridonC 2008 Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis J Rheumatol 35 1256 1264 Search in Google Scholar

Bowman SJ, Fox R, Dörner T et al. (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399:161–171. https://doi.org/10.1016/S0140-6736(21)02251-0 BowmanSJ FoxR DörnerT 2022 Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial Lancet 399 161 171 https://doi.org/10.1016/S0140-6736(21)02251-0 Search in Google Scholar

Cai J, Gao D, Liu D et al. (2023) Telitacicept for autoimmune nephropathy. Front Immunol 14:1169084. https://doi.org/10.3389/FIMMU.2023.1169084 CaiJ GaoD LiuD 2023 Telitacicept for autoimmune nephropathy Front Immunol 14 1169084 https://doi.org/10.3389/FIMMU.2023.1169084 Search in Google Scholar

Cao Y, Lu G, Chen X et al. (2020) BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF κB signaling pathway in glomerular mesangial cells. Mol Med Rep 21:795–805. https://doi.org/10.3892/MMR.2019.10870 CaoY LuG ChenX 2020 BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF κB signaling pathway in glomerular mesangial cells Mol Med Rep 21 795 805 https://doi.org/10.3892/MMR.2019.10870 Search in Google Scholar

Caza TN, Storey AJ, Hassen SI et al. (2023) Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int 103:593–606. https://doi.org/10.1016/j.kint.2023.01.001 CazaTN StoreyAJ HassenSI 2023 Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry Kidney Int 103 593 606 https://doi.org/10.1016/j.kint.2023.01.001 Search in Google Scholar

Chan J, Walters GD, Puri P et al. (2023) Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol 7:37. https://doi.org/10.1186/S41927-023-00358-3 ChanJ WaltersGD PuriP 2023 Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE) BMC Rheumatol 7 37 https://doi.org/10.1186/S41927-023-00358-3 Search in Google Scholar

Cheung CK, Barratt J, Liew A et al. (2024) The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol 3:1346769. https://doi.org/10.3389/FNEPH.2023.1346769 CheungCK BarrattJ LiewA 2024 The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies Front Nephrol 3 1346769 https://doi.org/10.3389/FNEPH.2023.1346769 Search in Google Scholar

Currie EG, Coburn B, Porfilio EA et al. (2022) Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight 7:e141289. https://doi.org/10.1172/jci.insight.141289 CurrieEG CoburnB PorfilioEA 2022 Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses JCI Insight 7 e141289 https://doi.org/10.1172/jci.insight.141289 Search in Google Scholar

Evans LS, Lewis KE, DeMonte D et al. (2023) Povetacicept, an enhanced dual APRIL/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol 75:1187–1202. https://doi.org/10.1002/art.42462 EvansLS LewisKE DeMonteD 2023 Povetacicept, an enhanced dual APRIL/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases Arthritis Rheumatol 75 1187 1202 https://doi.org/10.1002/art.42462 Search in Google Scholar

Feng J, HU Y, Chang AH et al. (2023) CD19/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus – safety and preliminary efficacy data from a phase I clinical study. Blood 142:4835. https://doi.org/10.1182/blood-2023-186669 FengJ HUY ChangAH 2023 CD19/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus – safety and preliminary efficacy data from a phase I clinical study Blood 142 4835 https://doi.org/10.1182/blood-2023-186669 Search in Google Scholar

Figgett WA, Deliyanti D, Fairfax KA et al. (2015) Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J Autoimmun 61:9–16. https://doi.org/10.1016/j.jaut.2015.04.007 FiggettWA DeliyantiD FairfaxKA 2015 Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers J Autoimmun 61 9 16 https://doi.org/10.1016/j.jaut.2015.04.007 Search in Google Scholar

Forero-Delgadillo J, Ochoa V, Restrepo JM et al. (2022) B-cell activating factor (BAFF) and its receptors' expression in pediatric nephrotic syndrome is associated with worse prognosis. PLoS One 17:e0277800. https://doi.org/10.1371/journal.pone.0277800 Forero-DelgadilloJ OchoaV RestrepoJM 2022 B-cell activating factor (BAFF) and its receptors' expression in pediatric nephrotic syndrome is associated with worse prognosis PLoS One 17 e0277800 https://doi.org/10.1371/journal.pone.0277800 Search in Google Scholar

Furie RA, Aroca G, Cascino MD et al. (2022a) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100–107. https://doi.org/10.1136/annrheumdis-2021-220920 FurieRA ArocaG CascinoMD 2022a B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial Ann Rheum Dis 81 100 107 https://doi.org/10.1136/annrheumdis-2021-220920 Search in Google Scholar

Furie R, Petri M, Zamani O et al. (2011) A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Reum 63:3918–3930. https://doi.org/10.1002/ART.30613 FurieR PetriM ZamaniO 2011 A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis Reum 63 3918 3930 https://doi.org/10.1002/ART.30613 Search in Google Scholar

Furie R, Rovin BH, Houssiau F et al. (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117–1128. https://doi.org/10.1056/NEJMoa2001180 FurieR RovinBH HoussiauF 2020 Two-year, randomized, controlled trial of belimumab in lupus nephritis N Engl J Med 383 1117 1128 https://doi.org/10.1056/NEJMoa2001180 Search in Google Scholar

Furie R, Rovin BH, Houssiau F et al. (2022b) Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol 17:1620–1630. https://doi.org/10.2215/CJN.02520322 FurieR RovinBH HoussiauF 2022b Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study Clin J Am Soc Nephrol 17 1620 1630 https://doi.org/10.2215/CJN.02520322 Search in Google Scholar

Furie RA, Rovin BH, Garg JP et al. (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471–1483. https://doi.org/10.1056/NEJMoa2410965 FurieRA RovinBH GargJP 2025 Efficacy and safety of obinutuzumab in active lupus nephritis N Engl J Med 392 1471 1483 https://doi.org/10.1056/NEJMoa2410965 Search in Google Scholar

Gabay C, Krenn V, Bosshard C et al. (2009) Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 11:R144. https://doi.org/10.1186/ar2817 GabayC KrennV BosshardC 2009 Synovial tissues concentrate secreted APRIL Arthritis Res Ther 11 R144 https://doi.org/10.1186/ar2817 Search in Google Scholar

Gordon C, Bassi R, Chang P et al. (2019) Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. Rheumatol Adv Pract 3:rkz021. https://doi.org/10.1093/rap/rkz021 GordonC BassiR ChangP 2019 Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme Rheumatol Adv Pract 3 rkz021 https://doi.org/10.1093/rap/rkz021 Search in Google Scholar

Groom JR, Fletcher CA, Walters SN et al. (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204:1959–1971. https://doi.org/10.1084/jem.20062567 GroomJR FletcherCA WaltersSN 2007 BAFF and MyD88 signals promote a lupuslike disease independent of T cells J Exp Med 204 1959 1971 https://doi.org/10.1084/jem.20062567 Search in Google Scholar

Han SS, Yang SH, Jo HA et al. (2018) BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. Oncotarget 9:3292–3302. https://doi.org/10.18632/Oncotarget.23232 HanSS YangSH JoHA 2018 BAFF and APRIL expression as an autoimmune signature of membranous nephropathy Oncotarget 9 3292 3302 https://doi.org/10.18632/Oncotarget.23232 Search in Google Scholar

Huang SP, Snedecor SJ, Nanji S et al. (2022) Real-world effectiveness of belimumab in systemic lupus erythematosus: A systematic literature review. Rheumatol Ther 9:975–991. https://doi.org/10.1007/S40744-022-00454-9 HuangSP SnedecorSJ NanjiS 2022 Real-world effectiveness of belimumab in systemic lupus erythematosus: A systematic literature review Rheumatol Ther 9 975 991 https://doi.org/10.1007/S40744-022-00454-9 Search in Google Scholar

Huard B, Tran NL, Benkhoucha M et al. (2012) Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 7:e31837. https://doi.org/10.1371/journal.pone.0031837 HuardB TranNL BenkhouchaM 2012 Selective APRIL blockade delays systemic lupus erythematosus in mouse PLoS One 7 e31837 https://doi.org/10.1371/journal.pone.0031837 Search in Google Scholar

Jacob CO, Yu N, Sindhava V et al. (2015) Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors. Arthritis Rheumatol 67:2523–2535. https://doi.org/10.1002/art.39210 JacobCO YuN SindhavaV 2015 Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors Arthritis Rheumatol 67 2523 2535 https://doi.org/10.1002/art.39210 Search in Google Scholar

Jin HZ, Cai ML, Wang X et al. (2025) Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study. Clin Rheumatol 44:247–256. https://doi.org/10.1007/s10067-024-07266-y JinHZ CaiML WangX 2025 Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study Clin Rheumatol 44 247 256 https://doi.org/10.1007/s10067-024-07266-y Search in Google Scholar

Khare SD, Sarosi I, Xia XZ et al. (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97:3370–3375. https://doi.org/10.1073/pnas.97.7.3370 KhareSD SarosiI XiaXZ 2000 Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice Proc Natl Acad Sci USA 97 3370 3375 https://doi.org/10.1073/pnas.97.7.3370 Search in Google Scholar

Kiryluk K, Li Y, Scolari F et al. (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196. https://doi.org/10.1038/ng.3118 KirylukK LiY ScolariF 2014 Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens Nat Genet 46 1187 1196 https://doi.org/10.1038/ng.3118 Search in Google Scholar

Kiyama K, Kawabata D, Hosono Y et al. (2012) Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther 14:R86. https://doi.org/10.1186/ar3810 KiyamaK KawabataD HosonoY 2012 Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance Arthritis Res Ther 14 R86 https://doi.org/10.1186/ar3810 Search in Google Scholar

Lafayette R, Barbour S, Israni R et al. (2024) A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int 105:1306–1315. https://doi.org/10.1016/j.kint.2024.03.012 LafayetteR BarbourS IsraniR 2024 A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy Kidney Int 105 1306 1315 https://doi.org/10.1016/j.kint.2024.03.012 Search in Google Scholar

Lafayette RA, Canetta PA, Rovin BH et al. (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313. https://doi.org/10.1681/asn.2016060640 LafayetteRA CanettaPA RovinBH 2017 A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction J Am Soc Nephrol 28 1306 1313 https://doi.org/10.1681/asn.2016060640 Search in Google Scholar

Li Z, Chen P, Zhang Y et al. (2024) Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy. Ren Fail 46:2391069. https://doi.org/10.1080/0886022X.2024.2391069 LiZ ChenP ZhangY 2024 Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy Ren Fail 46 2391069 https://doi.org/10.1080/0886022X.2024.2391069 Search in Google Scholar

Luo Y, Qie Y, Gadd ME et al. (2023) Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies. Cancer Immunol Immunother 72:4031–4047. https://doi.org/10.1007/S00262-023-03537-w LuoY QieY GaddME 2023 Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies Cancer Immunol Immunother 72 4031 4047 https://doi.org/10.1007/S00262-023-03537-w Search in Google Scholar

Lv J, Liu L, Hao C et al. (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499–506. https://doi.org/10.1016/j.ekir.2022.12.014 LvJ LiuL HaoC 2023 Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria Kidney Int Rep 8 499 506 https://doi.org/10.1016/j.ekir.2022.12.014 Search in Google Scholar

Mackensen A, Müller F, Mougiakakos D et al. (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28:2124–2132. https://doi.org/10.1038/s41591-022-02017-5 MackensenA MüllerF MougiakakosD 2022 Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus Nat Med 28 2124 2132 https://doi.org/10.1038/s41591-022-02017-5 Search in Google Scholar

Marín-Rosales M, Palafox-Sánchez CA, Franco-Topete RA et al. (2022) Renal tissue expression of BAFF and BAFF receptors is associated with proliferative lupus nephritis. J Clin Med 12:71. https://doi.org/10.3390/jcm12010071 Marín-RosalesM Palafox-SánchezCA Franco-TopeteRA 2022 Renal tissue expression of BAFF and BAFF receptors is associated with proliferative lupus nephritis J Clin Med 12 71 https://doi.org/10.3390/jcm12010071 Search in Google Scholar

Mathur M, Barratt J, Chacko B et al. (2024) A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. New Engl J Med 390:20–31. https://doi.org/10.1056/NEJMOA2305635 MathurM BarrattJ ChackoB 2024 A phase 2 trial of sibeprenlimab in patients with IgA nephropathy New Engl J Med 390 20 31 https://doi.org/10.1056/NEJMOA2305635 Search in Google Scholar

Mathur M, Chan TM, Oh KH et al. (2023) A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence. J Clin Med 12:6927. https://doi.org/10.3390/jcm12216927 MathurM ChanTM OhKH 2023 A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence J Clin Med 12 6927 https://doi.org/10.3390/jcm12216927 Search in Google Scholar

McCarthy DD, Kujawa J, Wilson C et al. (2011) Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121:3991–4002. https://doi.org/10.1172/JCI45563 McCarthyDD KujawaJ WilsonC 2011 Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy J Clin Invest 121 3991 4002 https://doi.org/10.1172/JCI45563 Search in Google Scholar

Mo S, Li Y, He J et al. (2024) Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis. Front Med 11:1472019. https://doi.org/10.3389/fmed.2024.1472019 MoS LiY HeJ 2024 Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis Front Med 11 1472019 https://doi.org/10.3389/fmed.2024.1472019 Search in Google Scholar

Mougiakakos D, Krönke G, Völkl S et al. (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385:567–569. https://doi.org/10.1056/NEJMc2107725 MougiakakosD KrönkeG VölklS 2021 CD19-targeted CAR T cells in refractory systemic lupus erythematosus N Engl J Med 385 567 569 https://doi.org/10.1056/NEJMc2107725 Search in Google Scholar

Mucha K, Pac M, Pączek L (2023) Omics are getting us closer to understanding IgA nephropathy. Arch Immunol Ther Exp 71:12. https://doi.org/10.1007/S00005-023-00677-w MuchaK PacM PączekL 2023 Omics are getting us closer to understanding IgA nephropathy Arch Immunol Ther Exp 71 12 https://doi.org/10.1007/S00005-023-00677-w Search in Google Scholar

Nawata A, Nakayamada S, Hisano S et al. (2023) Original research: differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis. Lupus Sci Med 10:e000962. https://doi.org/10.1136/lupus-2023-000962 NawataA NakayamadaS HisanoS 2023 Original research: differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis Lupus Sci Med 10 e000962 https://doi.org/10.1136/lupus-2023-000962 Search in Google Scholar

Netti GS, Infante B, Spadaccino F et al. (2019) Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy. J Immunol Res 2019:8483650. https://doi.org/10.1155/2019/8483650 NettiGS InfanteB SpadaccinoF 2019 Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy J Immunol Res 2019 8483650 https://doi.org/10.1155/2019/8483650 Search in Google Scholar

Neusser MA, Lindenmeyer MT, Edenhofer I et al. (2011) Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24:98–107. https://doi.org/10.1038/modpathol.2010.184 NeusserMA LindenmeyerMT EdenhoferI 2011 Intrarenal production of B-cell survival factors in human lupus nephritis Mod Pathol 24 98 107 https://doi.org/10.1038/modpathol.2010.184 Search in Google Scholar

Oniszczuk J, Beldi-Ferchiou A, Audureau E et al. (2021) Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol Dial Transplant 36:609–617. https://doi.org/10.1093/ndt/gfaa279 OniszczukJ Beldi-FerchiouA AudureauE 2021 Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults Nephrol Dial Transplant 36 609 617 https://doi.org/10.1093/ndt/gfaa279 Search in Google Scholar

Petrou D, Kalogeropoulos P, Liapis G et al. (2023) IgA nephropathy: current treatment and new insights. Antibodies 12:40. https://doi.org/10.3390/antib12020040 PetrouD KalogeropoulosP LiapisG 2023 IgA nephropathy: current treatment and new insights Antibodies 12 40 https://doi.org/10.3390/antib12020040 Search in Google Scholar

Piantoni S, Korsten P (2022) Rituximab-a B cell targeted therapy in systemic lupus erythematosus: where do we stand? Rheumatology 61:1752–1755. https://doi.org/10.1093/rheumatology/keac095 PiantoniS KorstenP 2022 Rituximab-a B cell targeted therapy in systemic lupus erythematosus: where do we stand? Rheumatology 61 1752 1755 https://doi.org/10.1093/rheumatology/keac095 Search in Google Scholar

Roos I, Hughes S, McDonnell G et al. (2023) Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol 80:789–797. https://doi.org/10.1001/jamaneurol.2023.1625 RoosI HughesS McDonnellG 2023 Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis JAMA Neurol 80 789 797 https://doi.org/10.1001/jamaneurol.2023.1625 Search in Google Scholar

Sallustio F, Curci C, Chaoul N et al. (2021) High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients. Nephrol Dial Transplant 36:452–464. https://doi.org/10.1093/ndt/gfaa264 SallustioF CurciC ChaoulN 2021 High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients Nephrol Dial Transplant 36 452 464 https://doi.org/10.1093/ndt/gfaa264 Search in Google Scholar

Samy E, Wax S, Huard B et al. (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 36:3–19. https://doi.org/10.1080/08830185.2016.1276903 SamyE WaxS HuardB 2017 Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases Int Rev Immunol 36 3 19 https://doi.org/10.1080/08830185.2016.1276903 Search in Google Scholar

Selvaskandan H, Barratt J, Cheung CK (2023) Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep 9:203–213. https://doi.org/10.1016/j.ekir.2023.11.026 SelvaskandanH BarrattJ CheungCK 2023 Novel treatment paradigms: primary IgA nephropathy Kidney Int Rep 9 203 213 https://doi.org/10.1016/j.ekir.2023.11.026 Search in Google Scholar

Suzuki H, Kiryluk K, Novak J et al. (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803. https://doi.org/10.1681/asn.2011050464 SuzukiH KirylukK NovakJ 2011 The pathophysiology of IgA nephropathy J Am Soc Nephrol 22 1795 1803 https://doi.org/10.1681/asn.2011050464 Search in Google Scholar

Trimarchi H, Barratt J, Radhakrishnan J et al. (2024) WCN24-1837 beyond: a phase 3, randomized, double-blind, placebo controlled trial of zigakibart in adults with IgA nephropathy. Kidney Int Rep 9:S177. https://doi.org/10.1016/j.ekir.2024.02.362 TrimarchiH BarrattJ RadhakrishnanJ 2024 WCN24-1837 beyond: a phase 3, randomized, double-blind, placebo controlled trial of zigakibart in adults with IgA nephropathy Kidney Int Rep 9 S177 https://doi.org/10.1016/j.ekir.2024.02.362 Search in Google Scholar

Union Register of Medicinal Products – Public Health – European Commission. (2024) Union register of medicinal products for human use. https://ec.europa.eu/health/documents/community-register/html/h067.htm. Accessed 25 November 2024. Union Register of Medicinal Products – Public Health – European Commission 2024 Union register of medicinal products for human use https://ec.europa.eu/health/documents/community-register/html/h067.htm. Accessed 25 November 2024. Search in Google Scholar

Vosters JL, Roescher N, Polling EJ et al. (2012) The expression of APRIL in Sjögren's syndrome: aberrant expression of APRIL in the salivary gland. Rheumatology (Oxford) 51:1557–1562. https://doi.org/10.1093/RHEUMATOLOGY/KES080 VostersJL RoescherN PollingEJ 2012 The expression of APRIL in Sjögren's syndrome: aberrant expression of APRIL in the salivary gland Rheumatology (Oxford) 51 1557 1562 https://doi.org/10.1093/RHEUMATOLOGY/KES080 Search in Google Scholar

Wallace DJ, Isenberg DA, Morand EF et al. (2021) Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology 60:5379–5389. https://doi.org/10.1093/rheumatology/keab115 WallaceDJ IsenbergDA MorandEF 2021 Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus Rheumatology 60 5379 5389 https://doi.org/10.1093/rheumatology/keab115 Search in Google Scholar

Wang W, He S, Zhang W et al. (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83:1304–1314. https://doi.org/10.1136/ARD-2024-225785 WangW HeS ZhangW 2024 BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial Ann Rheum Dis 83 1304 1314 https://doi.org/10.1136/ARD-2024-225785 Search in Google Scholar

Wang X, Dong Z, Awuah D et al. (2022) CD19/BAFF-R dual-targeted CAR T cells for treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia 36:1015–1024. https://doi.org/10.1038/S41375-021-01477-X WangX DongZ AwuahD 2022 CD19/BAFF-R dual-targeted CAR T cells for treatment of mixed antigen-negative variants of acute lymphoblastic leukemia Leukemia 36 1015 1024 https://doi.org/10.1038/S41375-021-01477-X Search in Google Scholar

Wong DP, Roy NK, Zhang K et al. (2022) A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 13:217. https://doi.org/10.1038/s41467-021-27853-w WongDP RoyNK ZhangK 2022 A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers Nat Commun 13 217 https://doi.org/10.1038/s41467-021-27853-w Search in Google Scholar

Worley K, Milligan S, Rubin B (2023) Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data. Lupus Sci Med 10:e001024. https://doi.org/10.1136/LUPUS-2023-001024 WorleyK MilliganS RubinB 2023 Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data Lupus Sci Med 10 e001024 https://doi.org/10.1136/LUPUS-2023-001024 Search in Google Scholar

Xiao X, Huang S, Chen S et al. (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res 40:367. https://doi.org/10.1186/S13046-021-02148-6 XiaoX HuangS ChenS 2021 Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies J Exp Clin Cancer Res 40 367 https://doi.org/10.1186/S13046-021-02148-6 Search in Google Scholar

Xin G, Shi W, Xu LX et al. (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683–690. https://doi.org/10.5301/JN.5000218 XinG ShiW XuLX 2013 Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features J Nephrol 26 683 690 https://doi.org/10.5301/JN.5000218 Search in Google Scholar

Yu XQ, Li M, Zhang H et al. (2011) A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44:178–182. https://doi.org/10.1038/NG.1047 YuXQ LiM ZhangH 2011 A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy Nat Genet 44 178 182 https://doi.org/10.1038/NG.1047 Search in Google Scholar

Zhai YL, Zhu L, Shi SF et al. (2016) Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore) 95:e3099. https://doi.org/10.1097/MD.0000000000003099 ZhaiYL ZhuL ShiSF 2016 Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy Medicine (Baltimore) 95 e3099 https://doi.org/10.1097/MD.0000000000003099 Search in Google Scholar

Zhang L, Jin H, Wang D et al. (2023) Case report: successful treatment of refractory membranous nephropathy with telitacicept. Front Immunol 14:1268929. https://doi.org/10.3389/fimmu.2023.1268929 ZhangL JinH WangD 2023 Case report: successful treatment of refractory membranous nephropathy with telitacicept Front Immunol 14 1268929 https://doi.org/10.3389/fimmu.2023.1268929 Search in Google Scholar

Zheng N, Wang D, Ming H et al. (2015) BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R. BMC Nephrol 16:72. https://doi.org/10.1186/S12882-015-0064-y ZhengN WangD MingH 2015 BAFF promotes proliferation of human mesangial cells through interaction with BAFF-R BMC Nephrol 16 72 https://doi.org/10.1186/S12882-015-0064-y Search in Google Scholar

Zhuang Y, Lu H, Li J (2023) Advances in the treatment of IgA nephropathy with biological agents. Chronic Dis Transl Med 10:1–11. https://doi.org/10.1002/CDT3.104 ZhuangY LuH LiJ 2023 Advances in the treatment of IgA nephropathy with biological agents Chronic Dis Transl Med 10 1 11 https://doi.org/10.1002/CDT3.104 Search in Google Scholar